)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sensorion
Sensorion (ALSEN) investor relations material
Sensorion H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary23 Sep, 2026
Executive summary
Focus shifted to SENS-601 gene therapy for GJB2-related hearing loss after discontinuing SENS-501 due to a changing competitive landscape and greater unmet need in GJB2 indications; SENS-601 advanced with CTAs filed in France and Canada, French approval received in August 2026, and Fast Track status granted.
SENS-401, a small molecule for hearing preservation, completed proof-of-concept and Phase II studies in three indications; partnering opportunities are being explored.
Major management changes: Fred Chereau appointed CEO in June 2026, with interim CEO Amit Munshi earlier in the year; organizational restructuring proposed post-period.
Financial highlights
Cash, cash equivalents, and short-term deposits totaled €88.5 million at June 30, 2026, up from €47.5 million at December 31, 2025.
Operating expenses rose to €24.1 million from €19.1 million, driven by higher R&D (€16.4 million, up 9% YoY) and G&A (€7.7 million) costs.
Net loss widened to €20.7 million from €16.0 million year-over-year.
Equity increased to €81.6 million from €44.5 million at year-end 2025, reflecting a €60 million capital raise.
Outlook and guidance
Cash runway expected to fund operations through end of 2027, with no liquidity risk anticipated in the next twelve months.
First patient dosing for SENS-601 targeted by early 2027; US IND and Australia CTA submissions planned by year-end 2026.
Organizational restructuring under consideration to align resources with GJB2-GT focus; may have future financial impacts.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sensorion
- Gene therapy for GJB2 hearing loss enters clinic, with first dosing and data expected in 2027.ALSEN
Status update - Advancing gene therapy for GJB2 hearing loss, with clinical trials and strong financial backing.ALSENCorporate presentation
- Advancing gene therapy and small molecule programs for hearing loss with strong clinical progress.ALSENCorporate presentation
- Gene therapy pipeline advanced, €60m financing secured, and cash runway extended to mid-2027.ALSENH2 2025
- Positive clinical progress and strong cash reserves, despite a wider net loss.ALSENH1 2025
- Gene therapies and small molecules advance toward key milestones in hearing loss treatment.ALSENCorporate Presentation
- Sensorion achieved major clinical milestones and secured €87.3m to fund operations into 2025.ALSENH1 2024
- Advancing gene therapies and small molecules, Sensorion targets global leadership in hearing loss.ALSENCorporate Presentation
- Gene therapy pipeline advances with early clinical success and strong strategic partnerships.ALSEN43rd Annual J.P. Morgan Healthcare Conference 2025
Next Sensorion earnings date
H2 202617 Mar, 2027
Sensorion
Next Sensorion earnings date
H2 202617 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sensorion SA is a clinical-stage biotechnology company focused on developing therapeutic solutions for inner ear disorders, particularly targeting hearing loss and balance disorders. The company's research and development efforts span from molecular biology to clinical research, aiming to address unmet medical needs related to inner ear pathologies. Sensorion's work includes developing drug treatments designed to restore, treat, and prevent these conditions, leveraging its expertise in animal pharmacology, toxicology, and clinical studies. The company is headquartered in Montpellier, France, and its shares are listed on the Euronext Paris.